Evidence map›Paper›PMID 29036790›Full record

Trial reportCancer biomarkers : section A of Disease markers2017

Predictors for the efficacy of Endostar combined with neoadjuvant chemotherapy for stage IIIA (N2) NSCLC.

Xiaoliang Zhao, Xiaohua Wen, Wei Wei, Yanjun Su, Jian You, Liqun Gong, Zhenfa Zhang, Meng Wang, Jianyu Xiao, Xiyin Wei and 1 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer biomarkers : section A of Disease markers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Xiaoliang ZhaoDepartment of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Xiaohua WenTianjin University of Traditional Chinese Medicine, Tianjin 300193, China.
Wei WeiDepartment of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Yanjun SuDepartment of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Jian YouDepartment of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Liqun GongDepartment of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Zhenfa ZhangDepartment of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Meng WangDepartment of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Jianyu XiaoTianjin Lung Cancer Center, Tianjin 300060, China.
Xiyin WeiTianjin Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin 300060, China.
Changli WangDepartment of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Tianjin Medical University Cancer Institute and Hospital · CNTianjin University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEndostar (rh-endostatin) is a new recombinant human endostatin, which could inhibit cell proliferation, angiogenesis, and tumor growth.

objectiveTo explore anti-angiogenesis short-term efficacy combined with neoadjuvant chemotherapy for stage IIIA (N2) non-small cell lung cancer (NSCLC), and identify the potential predictive factors.

methodsWe pathologically examined 26 patients diagnosed with stage IIIA (N2) NSCLC who received NP chemotherapy alone or combined with Endostar, respectively.

resultsOur results indicated that total clinical benefit rate (CBR) 87.5% and 64% (p= 0.76), respectively. The clinical benefit (CB) patients in the treatment group showed significant changes in endothelial progenitor cells (EPC), vascular endothelial growth factor (VEGF), blood flow (BF), permeability surface (PMS), and microvascular density (MVD) before and after treatment. Compared with CB patients in the control group, changes in EPC and MVD (only) before and after treatment were significant. The variation of EPC, PMS, and MVD before and after treatment in the treatment group showed positive correlation with tumor regression rate (TRR) and the variation of MVD, whereas those of EPC and PMS demonstrated positive correlations with variation of MVD before and after treatment.

conclusionOur findings suggested that PMS and EPC may be used as a predictive factor for the short-term efficacy of the combined therapy in NSCLC.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungCisplatinEndostatinsEndothelial Progenitor CellsFemaleHumansLung NeoplasmsMaleNeoadjuvant TherapyNeoplasm StagingNeovascularization, PathologicPrognosisRecombinant ProteinsTreatment OutcomeVascular Endothelial Growth Factor ACisplatinendostar proteinEndostatinsRecombinant ProteinsVascular Endothelial Growth Factor AVinblastineVinorelbinecirculating endothelial progenitor cellsnon-small cell lung cancerperfusion imagingpredictorRH-endostatin

Identifiers

PMID29036790
PMCPMC13075752
OpenAlexW2763116808

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.